Blossom Wealth Management increased its stake in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 9.8% during the 1st quarter, Holdings Channel.com reports. The fund owned 7,541 shares of the biopharmaceutical company’s stock after purchasing an additional 670 shares during the quarter. Pfizer accounts for approximately 1.8% of Blossom Wealth Management’s portfolio, making the stock its 23rd largest position. Blossom Wealth Management’s holdings in Pfizer were worth $390,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also bought and sold shares of the company. Econ Financial Services Corp bought a new stake in shares of Pfizer during the fourth quarter valued at approximately $31,000. PYA Waltman Capital LLC purchased a new position in Pfizer during the fourth quarter valued at $31,000. Rinkey Investments purchased a new position in Pfizer during the fourth quarter valued at $32,000. Stuart Chaussee & Associates Inc. raised its stake in Pfizer by 108.3% during the first quarter. Stuart Chaussee & Associates Inc. now owns 625 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 325 shares during the last quarter. Finally, Bivin & Associates Inc. purchased a new position in Pfizer during the fourth quarter valued at $37,000. 66.50% of the stock is currently owned by institutional investors.
Pfizer Stock Down 1.1 %
Shares of NYSE:PFE opened at $50.82 on Thursday. Pfizer Inc. has a 52-week low of $40.51 and a 52-week high of $61.71. The stock has a market cap of $285.15 billion, a P/E ratio of 11.66, a price-to-earnings-growth ratio of 0.61 and a beta of 0.73. The business’s 50 day moving average is $51.39 and its 200 day moving average is $51.50. The company has a quick ratio of 1.13, a current ratio of 1.39 and a debt-to-equity ratio of 0.43.
Pfizer (NYSE:PFE – Get Rating) last announced its quarterly earnings data on Tuesday, May 3rd. The biopharmaceutical company reported $1.62 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.66 by ($0.04). Pfizer had a return on equity of 38.29% and a net margin of 26.97%. The firm had revenue of $25.66 billion during the quarter, compared to the consensus estimate of $24.73 billion. During the same period last year, the company earned $0.93 EPS. The firm’s revenue for the quarter was up 76.8% compared to the same quarter last year. Sell-side analysts predict that Pfizer Inc. will post 6.63 EPS for the current year.
Pfizer Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 6th. Shareholders of record on Wednesday, June 29th will be given a dividend of $0.40 per share. The ex-dividend date of this dividend is Thursday, July 28th. This represents a $1.60 annualized dividend and a yield of 3.15%. Pfizer’s dividend payout ratio (DPR) is presently 36.70%.
Analyst Ratings Changes
A number of brokerages have issued reports on PFE. Citigroup lifted their price objective on Pfizer from $46.00 to $57.00 and gave the company a “neutral” rating in a research note on Tuesday, April 5th. The Goldman Sachs Group set a $51.00 price objective on Pfizer in a research note on Wednesday, July 13th. Wells Fargo & Company lowered their price objective on Pfizer from $60.00 to $55.00 in a research note on Wednesday, May 4th. JPMorgan Chase & Co. set a $57.00 price objective on Pfizer in a research note on Tuesday, June 28th. Finally, Berenberg Bank set a $50.00 price target on Pfizer in a research note on Friday, May 27th. Nine investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $56.95.
Insider Buying and Selling at Pfizer
In other Pfizer news, EVP William R. Carapezzi, Jr. sold 32,908 shares of the stock in a transaction on Thursday, May 12th. The stock was sold at an average price of $50.00, for a total transaction of $1,645,400.00. Following the sale, the executive vice president now owns 38,146 shares of the company’s stock, valued at approximately $1,907,300. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Pfizer news, EVP William R. Carapezzi, Jr. sold 32,908 shares of the stock in a transaction on Thursday, May 12th. The stock was sold at an average price of $50.00, for a total transaction of $1,645,400.00. Following the sale, the executive vice president now owns 38,146 shares of the company’s stock, valued at approximately $1,907,300. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Jennifer B. Damico sold 4,000 shares of the stock in a transaction on Monday, May 16th. The shares were sold at an average price of $50.50, for a total value of $202,000.00. Following the sale, the senior vice president now directly owns 15,064 shares in the company, valued at approximately $760,732. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 41,126 shares of company stock valued at $2,075,003. 0.05% of the stock is currently owned by corporate insiders.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women’s health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
Receive News & Ratings for Pfizer Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pfizer and related companies with MarketBeat.com’s FREE daily email newsletter.